GET DAILY SIGNALSAxsome Therapeutics (AXSM) Reports +51.9% Revenue Growth and Narrows Losses in Q3
Key Takeaways
- Axsome Therapeutics reported third quarter 2026 total revenue of $259.7 million, up 51.9% year over year and surpassing a $1 billion annualized run rate.
- The company posted a net loss of $0.25 per share, a sharp improvement from a loss of $0.94 per share in the prior-year quarter and well ahead of the consensus estimate of a $0.69 loss.
- AUVELITY drove the quarter with net product sales of $207.6 million, up 52.5% year over year, supported by the launch in Alzheimer's disease agitation.
- SUNOSI generated $48.2 million in net product revenue, while SYMBRAVO contributed $3.9 million in net product sales, up 88% year over year.
- Despite the top- and bottom-line beats, shares fell sharply as investors weighed slowing sequential growth in some products and higher commercialization spending.
- The company reiterated that its roughly $314 million in cash is expected to fund operations through cash-flow positivity.
Why These Results Matter for Investors
Axsome Therapeutics is a central nervous system biopharmaceutical company, and its quarterly updates serve as an important barometer for how rapidly its commercial portfolio can scale toward profitability. The third quarter of 2026 represented the second straight period of accelerating revenue growth, pushing the company past a $1 billion annual run rate for the first time. I am particularly focused on AUVELITY's expansion into Alzheimer's disease agitation, the staying power of SUNOSI, and whether rising selling costs are translating into stronger prescription trends. With the firm still posting a net loss, this report provided a useful checkpoint on management's operating leverage narrative and the route to cash-flow breakeven.
Breaking Down the Quarter's Numbers
Axsome reported total revenue of $259.7 million for the third quarter of 2026, a 51.9% increase from $171.0 million in the year-ago period and above the consensus estimate of roughly $246.5 million. AUVELITY net product sales reached $207.6 million, up 52.5% year over year. SUNOSI net product revenue was $48.2 million, up 47% year over year, while SYMBRAVO net product sales were $3.9 million, up 88% year over year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The net loss narrowed to $12.9 million, or $0.25 per share, from $47.2 million, or $0.94 per share, a year earlier — beating the consensus estimate of a $0.69 loss by a wide margin. Selling, general and administrative expenses rose to $203.1 million from $150.2 million, while research and development spending increased to $50.6 million. The company ended the quarter with approximately $313.9 million in cash and cash equivalents.
Market Reaction and What Drove the Sell-Off
Despite a top- and bottom-line beat, AXSM shares declined sharply following the release, falling roughly 10% intraday. Investors appeared to focus on the quality and composition of the beat rather than its size. A portion of SUNOSI's growth was supported by an $8.5 million ex-U.S. milestone payment, and SYMBRAVO's sequential prescription growth slowed from roughly 30% in the prior quarter to about 7%. Management also signaled that gross-to-net discounts could tick up in the fourth quarter due to seasonality and did not reaffirm specific fourth-quarter or full-year 2027 guidance. These factors, combined with a stock that had already sold off heading into the report, tempered enthusiasm despite the record revenue figure.
Looking Ahead at Key Catalysts
Looking ahead, investors will be watching whether AUVELITY's momentum in both major depressive disorder and Alzheimer's disease agitation can be sustained. The company pointed to robust growth in new-to-brand prescriptions and a record number of new prescribers, which management expects to support continued refill demand in the coming quarters.
The pipeline offers a dense catalyst calendar. Topline results from the ENGAGE Phase 3 trial of solriamfetol in binge eating disorder are expected in the first quarter of 2027. The company also has a Prescription Drug User Fee Act target action date of May 1, 2027, for AXS-12 in cataplexy associated with narcolepsy.
Additional readouts are anticipated in the second half of 2027, including the SUSTAIN trial in shift work disorder, the FOCUS-2 and FOCUS-3 trials in attention-deficit/hyperactivity disorder, and the SUMMIT trial of AXS-05 in smoking cessation. On the cost side, investors will monitor SG&A trends now that the bulk of the sales force expansion is reflected in the run rate, as well as gross-to-net dynamics and any shifts in prescription data reporting that could affect the visibility of demand trends.
My Experience with Tickeron Tools
In my own analysis, I frequently rely on Tickeron’s AI-powered platforms to cross-check fundamentals and spot comparable names quickly. One tool I find especially useful for this kind of earnings review is the AI Screener, which lets me filter for similar biopharma names based on revenue trends, technical signals, and volatility metrics. It helps surface ideas efficiently without replacing my own judgment on the underlying story.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AXSM in upward trend: price may jump up because it broke its lower Bollinger Band on October 23, 2026
AXSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where AXSM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Bearish Trend Analysis
The 50-day moving average for AXSM moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for AXSM entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 49 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. AXSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AXSM's P/B Ratio (85.522) is slightly higher than the industry average of (3.104). P/E Ratio (-36.269) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (13.908) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services for pain and other nervous system
Industry Biotechnology
Advertisement